Boston Scientific Corp. (BSX)
NYSE
42.04
+0.46 (+1.11%)
Closed
Oct 8, 2026
Day's Range
41.3942.27
52 wk Range
41.39105.65
Financial Statements - BSX - Boston Scientific Corp.
Revenue
20.07B▲ 19.9%
Net Income
2.89B▲ 56.7%Net Margin 14.4%
EBITDA
5.33B▲ 22.7%
Free Cash Flow
3.40B▲ 43.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 20.07B | 16.74B | 14.24B | 12.68B | 11.88B | 9.91B |
| Cost of Goods | 6.22B | 5.25B | 4.34B | 3.95B | 3.71B | 3.51B |
| Gross Profit | 13.85B | 11.49B | 9.89B | 8.72B | 8.17B | 6.40B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 3.97B | 3B | 2.41B | 2.03B | 1.82B | 684M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -267M | -521M | -188M | -434M | -412M | -405M |
| Pre Tax Income | 3.38B | 2.28B | 1.98B | 1.14B | 1.07B | -79M |
| Income Tax | 493M | 436M | 393M | 443M | 36M | 2M |
| Net Income | 2.89B | 1.84B | 1.59B | 698M | 1.04B | -82M |
| EPS Basic | 1.96 | 1.26 | 1.08 | 0.45 | 0.69 | -0.12 |
| EPS Diluted | 1.94 | 1.25 | 1.07 | 0.45 | 0.69 | -0.12 |
| Basic Shares Outstanding | 1.48B | 1.47B | 1.45B | 1.43B | 1.42B | 1.41B |
| Diluted Shares Outstanding | 1.48B | 1.47B | 1.45B | 1.43B | 1.42B | 1.41B |
| Ebit | 3.73B | 2.58B | 2.25B | 1.61B | 1.41B | 282M |
| Ebitda | 5.33B | 4.34B | 3.62B | 3.16B | 2.91B | 1.81B |
| Net Income Continuous Operations | 2.89B | 1.84B | 1.59B | 698M | 1.04B | -82M |
| Minority Interests | 6M | 8M | 1M | 0 | 0 | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
